TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma Jan 3, 2023 06:50AM
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma Dec 4, 2022 06:00PM
TherapeuticsMD (TXMD) Announces $7M Private Placement of Preferred Stock Oct 31, 2022 06:53AM
TherapeuticsMD Announces Additional $7 Million Private Placement Oct 31, 2022 06:50AM
TherapeuticsMD (TXMD) Announces $7M Private Placement Oct 3, 2022 06:51AM
View Older Stories

Oct 3, 2022 06:50AM TherapeuticsMD Announces $7 Million Private Placement
Sep 12, 2022 06:51AM TherapeuticsMD (TXMD) Appoints Brian Bernick and Mark Glickman as Interim Co-CEOs
Sep 12, 2022 06:50AM TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers
Aug 8, 2022 06:50AM TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022
Aug 1, 2022 06:51AM TherapeuticsMD (TXMD) Announces $15M Common and Preferred Stock Placement with Rubric Capital
Aug 1, 2022 06:50AM TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
Jul 13, 2022 09:25AM Pre-Open Movers: ironSource Surges on Buyback, Tech Stocks Fall on Hot CPI
Jul 13, 2022 06:56AM TherapeuticsMD (TXMD) Expects EW Healthcare Merger to Be Terminated After Unsuccessful Tender Offer
Jul 13, 2022 06:50AM TherapeuticsMD Announces Expiration of Tender Offer
May 31, 2022 06:05AM TherapeuticsMD (TXMD) Aggress to be Acquired by EW Healthcare Partners for $10/Share
May 31, 2022 06:00AM  TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD
May 20, 2022 09:43AM TherapeuticsMD (TXMD) Receives FDA Approval for sNDA for ANNOVERA
May 20, 2022 09:43AM TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®
May 10, 2022 04:05PM TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022
Apr 14, 2022 04:15PM TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million
Mar 7, 2022 07:40AM TherapeuticsMD (TXMD) to Divest vitaCare to GoodRx (GDRX)
Mar 7, 2022 07:40AM TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx
Mar 1, 2022 04:30PM TherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022
Dec 10, 2021 04:31PM FDA Does Not Approve TherapeuticsMD (TXMD) Requested Revisions to Manufacturing Testing Limits for ANNOVERA
Dec 10, 2021 04:30PM U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®
Dec 8, 2021 06:51AM TherapeuticsMD (TXMD) Settles US BIJUVA Patent Litigation with Amneal, Announces May 25, 2032 Generic Entry Date
Dec 8, 2021 06:50AM TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date
Nov 11, 2021 06:45AM TherapeuticsMD (TXMD) Appoints Hugh O’Dowd as CEO
Nov 11, 2021 06:45AM TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O’Dowd, as Chief Executive Officer
Oct 27, 2021 05:00PM TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021
Oct 15, 2021 05:33PM TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer
Sep 2, 2021 06:50AM Therapeutics MD Is Urging Women to ‘Take Pause’ During Menopause Awareness Month
Aug 23, 2021 06:50AM TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector
Aug 9, 2021 04:30PM TherapeuticsMD Announces Appointment of Hugh O’Dowd as President
Jul 26, 2021 06:50AM TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021
May 25, 2021 06:51AM TherapeuticsMD (TXMD) Announces Submission of Low Dose BIJUVA 0.5 mg/100 mg Supplemental New Drug Application to FDA
May 25, 2021 06:50AM TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA
May 24, 2021 07:00AM The Sun Sentinel Names TherapeuticsMD, Inc. a Winner of the South Florida Top Workplaces 2021 Award
May 3, 2021 07:00AM TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting
Apr 29, 2021 07:00AM TherapeuticsMD to Report First Quarter 2021 Results on May 6, 2021
Apr 8, 2021 04:07PM TherapeuticsMD (TXMD) and Theramex Announce Approval of BIJUVE Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA in Belgium
Apr 8, 2021 04:05PM TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium
Mar 1, 2021 07:00AM TherapeuticsMD Announces Participation in Upcoming Investor Conferences
Feb 23, 2021 04:05PM TherapeuticsMD to Report Fourth Quarter 2020 Results on March 2, 2021
Dec 29, 2020 07:00AM TherapeuticsMD Announces Participation in Upcoming Investor Conferences
Nov 9, 2020 06:55AM TherapeuticsMD® Announces Third Quarter 2020 Financial Results
Oct 29, 2020 07:00AM TherapeuticsMD to Report Third Quarter 2020 Results on November 9, 2020
Oct 26, 2020 04:05PM POPSUGAR Launches New Women’s Health Destination, “Full Disclosure,” in Collaboration With TherapeuticsMD
Oct 9, 2020 08:00AM TherapeuticsMD Supports the Importance of Empowering Women to Make Informed Choices about their Sexual and Reproductive Health
Sep 25, 2020 09:04AM TherapeuticsMD (TXMD) Provides Update on Third Quarter Progress
Sep 25, 2020 09:02AM TherapeuticsMD Provides Update on Third Quarter Progress
Sep 21, 2020 05:01PM Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA®
Sep 21, 2020 05:01PM Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA®
Sep 10, 2020 06:50AM TherapeuticsMD Announces Participation at Two Upcoming Virtual Investor Conferences
Sep 9, 2020 04:05PM TherapeuticsMD Announces Patent Updates for ANNOVERA®
View Older Stories